Nuvation Bio Inc. (NUVB)

NYSE: NUVB · IEX Real-Time Price · USD
1.980
+0.200 (11.24%)
At close: Feb 26, 2024, 4:00 PM
1.990
+0.010 (0.51%)
Pre-market: Feb 27, 2024, 8:24 AM EST
11.24%
Market Cap 431.32M
Revenue (ttm) n/a
Net Income (ttm) -82.86M
Shares Out 217.94M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,361,401
Open 1.800
Previous Close 1.780
Day's Range 1.800 - 1.990
52-Week Range 0.950 - 2.130
Beta 1.14
Analysts Strong Buy
Price Target 4.83 (+143.94%)
Earnings Date Mar 13, 2024

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) pla... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 53
Stock Exchange NYSE
Ticker Symbol NUVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price forecast is $4.83, which is an increase of 143.94% from the latest price.

Price Target
$4.83
(143.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

7 weeks ago - Business Wire

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

7 weeks ago - Business Wire

Nuvation Bio Announces Departure of Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB) (the “Company”) announced today that Jennifer Fox will be stepping down from her role as Chief Financial Officer to pursue a new opportunity. ...

3 months ago - Business Wire

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

4 months ago - Business Wire

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

7 months ago - Business Wire

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

9 months ago - Business Wire

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

10 months ago - Business Wire

Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candid...

1 year ago - Business Wire

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised to con...

1 year ago - PRNewsWire

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - July 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvat...

1 year ago - Newsfile Corp

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuva...

1 year ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NUVB #NUVB--The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

1 year ago - Business Wire

FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why

The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December...

1 year ago - Benzinga

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

2 years ago - Business Wire

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET fam...

2 years ago - Benzinga

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therape...

2 years ago - PRNewsWire

Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones

David Hung, M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P.

2 years ago - PRNewsWire

Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme

NEW YORK, Dec. 15, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therape...

2 years ago - PRNewsWire